Know Cancer

forgot password

Computerized Scheduling of Nicotine Inhaler Use

18 Years
67 Years
Not Enrolling
Esophageal Cancer, Head and Neck Cancer, Lung Cancer

Thank you

Trial Information

Computerized Scheduling of Nicotine Inhaler Use

OBJECTIVES: I. Determine the effect of program length on inhaler use compliance, latency to
smoking relapse, and gradual cessation of inhaler use in participants using a
computer-assisted program to schedule nicotine inhaler dosing for smoking cessation. II.
Compare fast and slow paced versions of computer-assisted scheduling of nicotine inhaler use
versus ad libitum nicotine inhaler use, in terms of smoking cessation rates, in these
participants. III. Compare these dosing conditions, in terms of adherence, initial dosing
levels, and successful tapering effects, in these participants.

OUTLINE: This is a randomized study. Participants are randomized to one of three arms. All
participants monitor their period of cigarette smoking for 7 days by pressing a data input
button on a hand-held computer every time they smoke. Arm I: Participants begin using a
nicotine inhaler according to the dosing instructions that come with it and monitor their
inhaler usage with the hand-held computer. Arm II: Participants are prompted by the
hand-held computer to use a nicotine inhaler based on their prior smoking habits. When
prompted, participants use the nicotine inhaler at a comfortable rate over 20 minutes. The
computer prompts participants at a fixed frequency and duration of inhaler use for 3 weeks
and then tapers the frequency and duration over 3-5 weeks. Arm III: Participants are
prompted by the hand-held computer and use a nicotine inhaler as in arm II. The computer
prompts participants at a fixed frequency and duration of inhaler use for 12 weeks and then
tapers the frequency and duration over 3-5 weeks. Participants keep a weekly diary of the
average number of cigarettes smoked, average number of inhaler sessions, and average length
of each session. Participants also record the date of any 24-hour smoking cessation and
relapse and complete a withdrawal symptoms questionnaire. Participants are followed at 1

PROJECTED ACCRUAL: A total of 480 participants will be accrued for this study.

Inclusion Criteria

DISEASE CHARACTERISTICS: Smoker with a daily smoking rate between 15 and 40 cigarettes per
day for at least 2 years Willing to quit smoking Willing to use a nicotine inhaler No
concurrent use of smokeless tobacco, pipes, or cigars

PATIENT CHARACTERISTICS: Age: 18 to 67 Performance status: Not specified Life expectancy:
Not specified Hematopoietic: Not specified Hepatic: No liver disease Renal: No kidney
disease Cardiovascular: No history of heart disease No high blood pressure Other: No
stomach ulcers No overactive thyroid Not pregnant or nursing No plans to become pregnant
within the next 6 months

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
Endocrine therapy: No concurrent insulin Radiotherapy: Not specified Surgery: Not
specified Other: At least 1 month since prior bupropion or antidepressants At least 1 year
since prior treatment for substance abuse No other concurrent nicotine replacement

Type of Study:


Study Design:

Primary Purpose: Prevention

Principal Investigator

William Riley, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Personal Improvement Computer Systems


United States: Federal Government

Study ID:




Start Date:

April 2001

Completion Date:

March 2004

Related Keywords:

  • Esophageal Cancer
  • Head and Neck Cancer
  • Lung Cancer
  • non-small cell lung cancer
  • small cell lung cancer
  • esophageal cancer
  • hypopharyngeal cancer
  • laryngeal cancer
  • nasopharyngeal cancer
  • oropharyngeal cancer
  • lip and oral cavity cancer
  • paranasal sinus and nasal cavity cancer
  • tongue cancer
  • Esophageal Diseases
  • Esophageal Neoplasms
  • Head and Neck Neoplasms
  • Lung Neoplasms



Personal Improvement Computer Systems, Incorporated Reston, Virginia  20191